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BACKGROUND: To evaluate the macrophage migration inhibitory factor and E-selectin levels in patients with
acute coronary syndrome.
MATERIALS/METHODS:We examined the plasma migration inhibitory factor and E-selectin levels in 87 patients
who presented with chest pain at our hospital. The patients were classified into two groups according to their
cardiac status. Sixty-five patients had acute myocardial infarction, and 22 patients had non-cardiac chest pain
(non-coronary disease). We designated the latter group of patients as the control group. The patients who
presented with acute myocardial infarction were further divided into two subgroups: ST-elevated myocardial
infarction (n=30) and non-ST elevated myocardial infarction (n=35).
RESULTS: We found higher plasma migration inhibitory factor levels in both acute myocardial infarction
subgroups than in the control group. However, the E-selectin levels were similar between the acute myocardial
infarction and control patients. In addition, we did not find a significant difference in the plasma migration
inhibitory factor levels between the ST elevated myocardial infarction and NST-elevated myocardial infarction
subgroups.
DISCUSSION: The circulating concentrations of migration inhibitory factor were significantly increased in acute
myocardial infarction patients, whereas the soluble E-selectin levels were similar between acute myocardial
infarction patients and control subjects. Our results suggest that migration inhibitory factor may play a role in
the atherosclerotic process.
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Coronary Artery Disease; Atherosclerosis.
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Atherosclerosis is a chronic inflammatory disease of the
arterial wall characterized by an influx of immunocompe-
tent mononuclear cells. Both humoral and cellular immune
mechanisms play a major role in the onset and progression
of atheromatous lesions (1–3). Various inflammatory media-
tors, including E-selectin, intracellular adhesion molecule-1
(ICAM-1), integrins and macrophage migration inhibi-
tory factor (MIF), have been found to play a role in the
pathogenesis of atherosclerosis. MIF is a pro-inflammatory
regulator of many acute and chronic inflammatory diseases
(4–7). During events such as acute myocardial infarction
(AMI), both hypoxia and oxidative stress induce the release
of MIF from cardiomyocytes via an atypical protein kinase
C-dependent export mechanism, subsequently resulting
in extracellular signal-regulated kinase activation (1,8,9).
E-selectin is a cellular adhesion molecule. Cellular adhesion
molecules are expressed by the vascular endothelium,
resulting in the adhesion and transendothelial migration
of circulating leukocytes. Therefore, E-selectin may play
a role in the interaction between activated endothelial
cells and leukocytes during the pathogenesis of athero-
sclerosis (10).
The aim of the current study was to determine the
severity of arterial damage in coronary artery disease (CAD)
and the correlation between inflammatory processes, as
reflected by the degree of myocardial ischemia, and the MIF
and E-selectin levels.
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& MATERIALS AND METHODS
Study samples
The present study was designed and performed as a
retrospective clinical trial at the I˙zmir Training and Research
Hospital. The study population included 87 subjects
consecutively admitted to our internal medicine department
from July 2012 to March 2013. Chest pain was the principal
complaint among the admitted patients.
The criteria for myocardial infarction were met based on the
observation of an increase and/or a decrease in the serum
levels of cardiac biomarkers, along with supportive evidence
in the form of hallmark symptoms, suggestive electrocardio-
graphic changes, or imaging evidence of the new loss of viable
myocardium or a new regional wall motion abnormality.
An elevation in the serum levels of cardiac biomarkers,
such as cardiac troponin and the myocardial band fraction of
creatine kinase (CK-MB), is an indicator of myocardial injury.
According to these criteria, we examined 87 patients who
were admitted with angina pectoris. Twenty-two of the 87
patients had non-cardiac disease (non-cardiac chest pain),
and 65 of the patients had AMI. We classified the patients
who had AMI into two subgroups according to ECG
findings. Thirty of the AMI patients had ST elevation on
ECG (STEMI) and thirty five patients had non- ST elevation
on ECG (NSTEMI). The 22 subjects who had non-cardiac
chest pain were designated as the control group. None of
the participants had used statins.
The plasma MIF and soluble E-selectin (sE-selectin) levels
were examined in all groups. Patients with a history of any
malignancy, osteoporosis, systemic or local infection, or
hepatic or renal disease (serum creatinine levels.1.5 mg/
dl) and patients receiving systemic glucocorticoids or
immunosuppressive therapy were excluded from the study.
This study was approved by the local ethics committee of
our institution. Written informed consent was obtained
from each patient.
Blood collection
Following overnight fasting, venous blood samples were
collected in the morning (08:00–09:00 AM) and centrifuged
at 2000 x g for 15 minutes prior to laboratory testing. The
serum glucose, total cholesterol, low-density lipoprotein
(LDL) cholesterol, triglyceride, and high-density lipoprotein
(HDL) cholesterol levels were measured using Randox
enzymatic kits and a Roche-Hitachi modular system. The
LDL cholesterol levels were calculated using the Friedewald
equation. The blood samples were divided into aliquots and
stored at -70 C˚ until the analysis was performed.
Measurement of the plasma MIF and E-selectin
levels
The plasma MIF levels were measured via a quantitative
sandwich human MIF ELISA (R&D Systems, Minneapolis,
MN, USA) using a monoclonal antibody against MIF. The
plasma concentrations of sE-selectin were determined using
enzyme immunoassays from Bender MedSystems Diagnostics
(Vienna, Austria). The inter-assay coefficient of variation (CV)
was ,10%.
Statistical analysis
The data were analyzed using Statistical Package for the
Social Sciences (SPSS) for Windows, version 10.0.
Categorical variables are expressed as frequencies and
percentages. The Kolmogorov-Smirnov (KS) test was used
to determine whether continuous variables were normally
distributed. According to the KS test, all variables displayed
a normal distribution. For comparison of the continuous
variables, Student’s t-test was used. Differences between the
categorical variables were analyzed using Fisher’s exact test.
p,0.05 was considered to be significant.
& RESULTS
The demographic characteristics of the AMI and control
groups are presented in Table 1. A total of 87 patients were
included in this study. Of these patients, the 22 patients
lacking coronary occlusion were designated as the control
group, whereas the 65 patients with AMI were divided into
two subgroups, NSTEMI (n = 35) and STEMI (n = 30). The
patients with CAD were compared with the controls
(Table 1). No statistically significant difference was found
in age, the sex ratio or body mass index (BMI) between the
two groups. No significant difference in the plasma sE-
selectin levels was observed between the patients with CAD
and the control patients. The plasma MIF levels were
significantly higher in the AMI group than in the control
group (p,0.001). In contrast, we did not detect any
Table 1 - Demographic and biochemical characteristics of the patients in the AMI and control groups.
Control group (n =22) AMI group (n=65) pa
Age, years 62.8¡1.1 57.8¡11.4 0.716
Female/male, n 10/12 18/47 0.176
Hip circumference, cm 104.6 ¡ 9.5 108.8¡8.4 0.518
Waist circumference, cm 86.1¡10.5 91.6¡10.0 0.911
Systolic blood pressure, mmHg 131.1¡18.9 128.8¡11.6 0.823
Diastolic blood pressure, mmHg 74.5¡9.1 73.3¡7.7 0.587
Glucose, mg/dL 121.0¡50.1 116.5¡47.4 0.730
Total cholesterol, mg/dL 193.5¡32.6 206.4¡37.0 0.113
HDL, mg/dL 47.2¡7.8 45.77¡6.2 0.336
LDL, mg/dL 117.3¡23.4 129.8¡35.2 0.187
Triglycerides, mg/dL 147.7¡30.4 168.5¡48.5 0.061
hs-CRP, ng/mL 0.64¡0.38 0.90¡0.30 0.003*
sE-selectin, ng/mL 55.16¡28 50¡22.7 0.412
MIF, pg/mL 2.21¡23 5.08¡23 ,0.001*
The results are presented as the means ¡ SD. aAn independent-samples t-test was used. A p value of ,0.05 was considered to be significant (*). AMI:
Acute myocardial infarction; HDL: High-density lipoprotein; hs-CRP: High-sensitivity C-reactive protein; LDL: Low-density lipoprotein; MIF: Macrophage
migration inhibitory factor.
MIF in Coronary Artery Disease
Yu¨ksel A et al.
CLINICS 2015;70(3):169-172
170
significant difference in the MIF or E-selectin levels between
the AMI subgroups.
The demographic and biochemical characteristics of the
STEMI and NSTEMI patients are presented in Table 2. No
significant difference in any demographic characteristic was
detected between the two subgroups. We determined that
the serum HDL levels were lower in the STEMI patients
than in the NSTEMI patients (p = 0.003). Common risk
factors, such as diabetes mellitus, arterial hypertension and
smoking, were similar between the two subgroups.
The use of antihypertensive medications, including
angiotensin II receptor antagonists and ACE inhibitors,
were similar. The high-sensitivity C-reactive protein (hs-
CRP) levels were similar between the STEMI and NSTEMI
subgroups. However, the hs-CRP levels in both subgroups
were remarkably higher than those in the control group.
& DISCUSSION
In the present study, we found that the circulating MIF
levels were elevated in subjects with AMI compared to
control subjects. Unexpectedly, the plasma sE-selectin levels
were not significantly different between the two groups.
Furthermore, neither the circulating MIF levels nor the sE-
selectin levels were significantly different between the
subjects with NSTEMI and STEMI.
It has been shown that the circulating E-selectin levels are
valuable for predicting systemic atherosclerosis but that
their predictive value is limited for CAD. In addition,
studies have demonstrated a relationship between the E-
selectin levels and systemic atherosclerosis but not
specific coronary atherosclerosis (11,12). In a study by Shyu
et al., the E-selectin levels were evaluated in groups of
subjects with AMI or unstable angina and in a control
group. The circulating E-selectin levels were not signifi-
cantly different between these three groups (12). Prugger
et al. demonstrated that elevated E-selectin levels
were independently and significantly associated with
ischemic stroke (13). Furthermore, it has been reported that
E-selectin gene polymorphisms are associated with an
increased risk of CAD (14). In our study, we found that the
circulating sE-selectin levels were not significantly different
between the subjects in the AMI and control groups or
between the subjects with STEMI and NSTEMI. In contrast
to our study results, many findings have supported the
concept that the E-selectin levels are associated with AMI;
our results may be related to the size of our study
population (15–17).
Additionally, we found that the MIF levels were
significantly higher in the AMI group than in the control
group (p,0.001). Our data suggest that elevated circulating
MIF levels may correlate with myocardial infarction. To
evaluate the potential correlation between the MIF levels
and the severity of myocardial infarction, we measured the
plasma MIF levels in both the STEMI and NSTEMI
subgroups. However, no significant difference was
observed between the two subgroups. The findings of our
study are in accordance with the literature demonstrating
the effect of MIF on the atherosclerotic process (6,18,19).
Moreover, the circulating MIF levels have been correlated
with infarct size based on cardiac magnetic resonance
imaging (20).
Increased circulating concentrations of MIF were detected
in patients with AMI. MIF may play a role in the
pathogenesis of myocardial ischemia. MIF contributes to
macrophage accumulation in the infarct area and plays a
pro-inflammatory role in macrophage/myocyte-mediated
damage during infarction (1,3,8,21). It has been reported that
MIF deficiency protects the heart from ischemia-reperfusion
injury in mice by suppressing inflammatory responses (22).
The present study contains some limitations: the sample
size was relatively small, and we did not evaluate MIF or E-
selectin gene polymorphisms.
It has become evident that MIF plays a major role in the
development of vascular disease and myocardial damage;
therefore, MIF is currently under intense investigation as a
therapeutic target (23). These studies may be useful in terms
of the prevention of high-mortality diseases related to
atherosclerosis. In the future, MIF may be targeted for the
prevention of atherosclerotic diseases. It has been demon-
strated that MIF plays a role in neointimal lesion formation.
The observations that the antibody-mediated inhibition of
MIF inhibits neointima formation and is associated with
reduced inflammation and cellular proliferation were first
identified in mice (24). MIF inhibition has been shown to
induce the stabilization and even the regression of athero-
sclerotic plaques (25,26).
Taken together, our results indicate that the circulating
MIF levels were increased in subjects with AMI and that
these levels were not significantly different between subjects
with NSTEMI and STEMI. The plasma sE-selectin levels
were not significantly different between subjects with AMI
and control subjects or between subjects with NSTEMI and
STEMI. Future studies are needed to generalize these
results.
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Table 2 - Demographic and biochemical characteristics of
the patients with mild or severe coronary artery disease.
NSTEMI (n= 35) STEMI (n = 30) pa
Age, years 56.2¡12 59.7¡10.5 0.221
Hip circumference, cm 108¡8.6 109.6¡8.2 0.447
Waist circumference, cm 91.7¡10.6 91.5¡9.5 0.941
Systolic blood pressure, mmHg 123.3¡10.4 124.5¡13.1 0.686
Diastolic blood pressure, mmHg 73.5¡7.1 73.1¡8.5 0.852
Glucose, mg/dL 114.3¡37.1 119.1¡57.7 0.699
Total cholesterol, mg/dL 204.4¡30.3 208.7¡43.9 0.643
HDL, mg/dL 47.8¡5.4 43.3¡6.3 0.003*
LDL, mg/dL 129.3¡34.1 130.3¡35.2 0.910
Triglycerides, mg/dL 147.7¡30.4 168.5¡36.9 0.114
hs-CRP, ng/mL 0.99¡0.48 0.85¡0.36 0.887
sE-selectin, ng/mL 53.2¡23.6 48.3¡21.6 0.392
MIF, pg/mL 5.09¡2.4 5.07¡2.1 0.970
The results are presented as the means¡ SD. aAn independent-samples t-
test was used. A p value of ,0.05 was considered to be significant (*).
HDL: High-density lipoprotein; hs-CRP: High-sensitivity C-reactive protein;
LDL: Low-density lipoprotein; NSTEMI: Non-ST-elevated myocardial
infarction; MIF: Macrophage migration inhibitory factor; STEMI: ST-
elevated myocardial infarction.
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